S-ketamine Prevents Postoperative Pain and Cognitive Dysfunction After Tibial Fracture

Sponsor
Tianjin Medical University General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04643132
Collaborator
(none)
120
1
3
12
10

Study Details

Study Description

Brief Summary

Purpose:

To explore effects of S-ketamine on postoperative pain and cognitive dysfunction after tibial fracture and orthopedic surgery.

To evaluate and examine the incidence of adverse effects with the purpose of selecting the optimum dose.

Condition or Disease Intervention/Treatment Phase
  • Drug: Normal saline
  • Drug: S-ketamine (low-dose)
  • Drug: S-ketamine (high-dose)
N/A

Detailed Description

With the increase in human life span, orthopedic injuries and subsequent repair surgery have become a major health problem which impairs the life quality of patients and burdens healthcare systems worldwide. Poor post-surgical pain control is a leading factor that hinders the physical rehabilitation and musculoskeletal functional recovery, and causes acute cognitive impairment and chronic pain syndrome. Also, existing treatments of opioids and non-steroidal anti-inflammatory drugs have potential drawbacks, which may in turn interfere with bone healing. Therefore, prophylaxis of fracture-associated pain is indispensable to postoperative comfort and satisfaction.

There is no denying the fact that pathologic pain is related to central glutaminergic system and N-methyl-d-aspartate (NMDA) receptor activation induced central sensitization. Also, we previously reported that neuroinflammation is associated with pain development and cognitive dysfunction. Ketamine, a NMDA receptor antagonist, is effective in reversing NMDA receptor activation underlying pain states. But the side effects of ketamine limit its clinical application, such as Delirium, gibberish and agitation. It is clarified that S-ketamine has lower side effects than ketamine and that antinociception of S-ketamine is stronger than ketamine. The following study is carried out to evaluate whether S-ketamine can prevent postoperative pain and cognitive impairment after tibial fracture and orthopedic surgery in patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
S-ketamine Prevents Tibial Fracture-associated Postoperative Pain and Cognitive Dysfunction After Orthopedic Surgery in Patients: a Randomized Double-blind Controlled Trial
Actual Study Start Date :
Dec 15, 2020
Anticipated Primary Completion Date :
Nov 15, 2021
Anticipated Study Completion Date :
Dec 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Normal saline in patients

After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.

Drug: Normal saline
After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
Other Names:
  • 0. 9% Sodium Chloride Injection
  • Active Comparator: S-ketamine at low dose in patients

    After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.

    Drug: S-ketamine (low-dose)
    After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
    Other Names:
  • Esketamine Hydrochloride Injection
  • Active Comparator: S-ketamine at high dose in patients

    After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.

    Drug: S-ketamine (high-dose)
    After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
    Other Names:
  • Esketamine Hydrochloride Injection
  • Outcome Measures

    Primary Outcome Measures

    1. Mechanical hyperalgesia threshold on the palms of feet [48 hours after surgery]

      The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament.

    Secondary Outcome Measures

    1. Pain Score (NRS) [48 hours after surgery]

      The pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10 = greatest imaginable pain.

    2. Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm [48 hours after surgery]

      The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament

    3. Time of First Postoperative Analgesic Requirement [1 hour after surgery]

      First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.

    4. Total Dose of First Postoperative Analgesic Requirement [1 hour after surgery]

      First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.

    5. Cumulative Sufentanyl Consumption [48 hours after surgery]

      Each patient was administered analgesics using a PCA (Patient-controlled analgesia) pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving PACU (Postanesthesia care unit). This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 48 hours postoperatively

    6. Occurrence of Side Effects [48 hours after surgery]

      Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus

    7. Mini-Mental State Examination (MMSE) [48 hours after surgery]

      Cognitive performance was assessed with Mini-Mental State Examination (MMSE).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Subject is scheduled to undergo tibial fracture with orthopedic surgery under a short general anesthesia of less than 2 hours

    2. Subject's American Society of Anesthesiologists physical status is I-II.

    3. The subject's parent/legally authorized guardian has given written informed consent to participate.

    Exclusion Criteria:
    1. Subject has a diagnosis of bronchial asthma, coronary heart disease, severe hypertension, renal failure or liver failure.

    2. Subject has a diagnosis of Insulin dependent diabetes.

    3. Subject is allergy and contraindication to S-ketamine.

    4. Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre- existing therapy with opioids.

    5. Subject has any contraindication for the use of patient-controlled analgesia (PCA).

    6. Subject is pregnant or breast-feeding.

    7. Subject is obese (body mass index >30kg/m^2).

    8. Subject is incapacity to comprehend pain assessment and cognitive assessment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tianjin Medical University General Hospital Tianjin China 300052

    Sponsors and Collaborators

    • Tianjin Medical University General Hospital

    Investigators

    • Study Director: Guolin Wang, MD, Tianjin Medical University General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Guolin Wang, Professor, Tianjin Medical University General Hospital
    ClinicalTrials.gov Identifier:
    NCT04643132
    Other Study ID Numbers:
    • GWang011
    First Posted:
    Nov 24, 2020
    Last Update Posted:
    Aug 13, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Guolin Wang, Professor, Tianjin Medical University General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 13, 2021